Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECRESCENDO
2020-002918-41Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- Jun 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pertuzumab, trastuzumab, paclitaxel, docetaxel and trastuzumab emtansine in breast cancer (2 cohorts), sponsored by Institut Jules Bordet. Primary endpoint: 3-year recurrence-free survival in HER2-enriched pCR population. Started Jun 2021; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2020-002918-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002918-41.